Last reviewed · How we verify

NCT03941249

Blod Biomarkers for Stroke

Status unknown Last updated 29 March 2022
What this trial tests

trial in Stroke in 150 participants. Status unknown.

Timeline
1 November 2017
Primary endpoint
30 April 2023
1 December 2023

Quick facts

Lead sponsorHelle Klingenberg Iversen, MD, DmSc
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment150
Start date1 November 2017
Primary completion30 April 2023
Estimated completion1 December 2023
Sites1 location across Denmark

Conditions studied

Sponsor

Helle Klingenberg Iversen, MD, DmSc

Who can join

18 and older, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the project is to investigate specific markers in blood samples from patients with stroke (ischemic or hemorrhagic). This could hopefully help in the early diagnostic to separate patients with ischemic stroke from those with hemorrhagic stroke as treatment are different and patients need to come quickly to the correct treatment site.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03941249.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing